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Androgen receptor (AR) modulation in human uteri and ovaries of 
long term androgen-treated transsexual female patients was investi- 
gated. Androgen receptor expression was evaluated immunohisto- 
chemically in the ovaries of 11 and the endometria and myometria of 
six androgen-treated transsexual female patients. This was compared 
with AR expression in the ovaries and uteri of premenopausal and 
postmenopausal women not receiving treatment and in 10 ovaries of 
female patients with polycystic ovarian disease (PCOD). In the nor- 
mal ovaries germinal epithelium, gramtlosa cells of antral follicles, 
corpus luteum, and thecaf and stromal cells exhibited moderate AR 
expression. The more intense and uniform staining of ovarian stroma 
of female transsexual patients and those of patients with PCOD com- 
pared with ovarian stroma of normal controls was most remarkable. 
This similarity in histology and diitribution of ARs supports the hy- 
pothesis that PCOD is an androgen-mediated disorder. Immunostain- 
ing for ARs was only occasionally detectable in the uteri of premeno- 
pausal and postmenopausal women. In contrast, myometrial and 
endometrial stroma of the uteri of female transsexual patients dis- 
played an intense and diffuse nuclear immunostaining, but glandular 
epitheha remained unstained. Western blot analysis of the ovaries and 
uterine myometrial tissue samples from transsexual female patients 
confirmed the presence of the llO-kd AR molecule. Because the 
androgen treatment of some transsexual female patients was discon- 
tinued 6 weeks before they underwent hysterospmgo-oophorec- 
tomy, our data indicate a stable and persistent androgen-induced 
up-regulation of AR expression in ovaries. HUM PATHOL 25:1198- 
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Women with female gender dysphoria (transsexu- 
alism) who prepare for gender reassignment receive 
prolonged androgen treatment while awaiting reassign- 
ment surgery. This group of patients receiving a high 
dose of exogenous androgen over a prolonged period 
of time provides a unique and ethically acceptable op- 
portunity to study the morphological and endocrino- 
logic effects of androgen on ovary and uterus. Histologi- 
cal changes in the genital tracts of transsexual female 
patients who received long term androgen therapy were 
described by Miller et al’ and Futterweit et al.’ Histologi- 
cal examination showed marked changes in cervical epi- 
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thelia and a variable degree of endometrial atrophy.‘,’ 
The ovaries showed an increased number of follicular 
cysts and an occasional corpus luteum. The finding of 
similar histological changes in ovaries of women ex- 
posed to exogenous androgens and in patients with 
polycystic ovarian disease (PCOD) suggests that the 
morphological changes observed in the latter indeed 
result from excess androgens.” It is not clear whether 
these androgens mediate effects by direct interaction 
with androgen receptors (AR) in the target cell or after 
their conversion into estrogens by estrogen receptors. 
The production of a monoclonal antibody desig- 
nated F39.4 specific for human ARs has permitted us 
to employ a simple immunohistochemical method for 
light microscopic visualization of ARs in normal human 
tissues, including testis, prostate, and cervix.4 A limited 
number of studies have described the localization of 
ARs in human endometrium.“-’ Hild-Petit0 et al” dem- 
onstrated the presence of ARs in the follicle and corpus 
luteum of primate ovary. Recently, the immunohisto- 
chemical localization of ARs in human ovary was stud- 
ied at various stages of the menstrual cycle and follicular 
development.” We also showed immunohistochemically 
the presence of ARs in ovarian carcinomas and in gran- 
ulosa cell tumors of ovary.” The immunohistochemical 
findings from the latter studies make it likely that in 
human ovary androgens may influence follicular re- 
cruitment and growth by a direct interaction of an- 
drogens with ARs.” 
This study was designed to investigate whether ex- 
posure of ovarian tissue to androgens results in altered 
AR expression in the different cell types. For that pur- 
pose AR expression was evaluated in normal ovaries 
and compared with that in ovaries of female transsexual 
patients treated with large doses of androgen and in 
ovaries of patients with PCOD. The histological changes 
observed in endometria of androgen-treated women 
could be the result of either a direct interaction of 
androgens with ARs or an indirect interaction by way 
of estrogens produced by aromatization of androgens. 
To explore the possibility of the former we examined 
the presence of ARs in endometria and myometria of 
uteri obtained from androgen-treated female transsex- 
ual patients. 
MATERIALS AND METHODS 
Patients 
Thirteen ovaries were obtained from 11 female-to-male 
transsexuals who underwent hysterectomy and bilateral oo- 
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phorectomy. Mean age at the time of surgery was 25 years 
(range, 18 to 35 years). Menstrual cycles were regular in all 
but three women before androgen therapy was started. Testos- 
terone treatment was given for a mean period of 21 months 
(range, 11 to 72 months) before surgery. One normal ovary 
frozen at autopsy, four paraffin-embedded ovaries from pre- 
menopausal women 31 to 46 years old, and seven ovaries from 
postmenopausal women who underwent surgery for nonendo- 
crine reasons provided a total of 12 normal ovaries as controls. 
Ten ovaries from patients 20 to 49 years old with documented 
PCOD, including one ovary frozen at autopsy, also were avail- 
able. 
activity of F39.4 with ARs is not influenced by ligand-induced 
transformation of the AR molecule.‘” No significant cross re- 
activity of F39.4 was seen with human progesterone, estrogen, 
or glucocorticoid receptors.“,‘” 
lmmunohistochemistry 
The following testosterone preparations were adminis- 
tered before surgery (Table 1): (1) 250 mg of Sustanon (30 
mg of testosterone propionate, 60 mg of T phenylpropionate, 
60 mg of T isohexanoate, and 100 mg of T undecanoate: 
Organon. Oss, The Netherlands) was given intramuscularly 
once every second week for a mean period of 25 months 
(range, 12 to 72 months) to three women; (2) 120 to 160 
mg/d of Andriol (40 mg of T undecanoate; Organon) was 
given orally for a mean period of 15 months (range, 12 to 21 
months) to seven women; and (3) 125 mg/d of dihydrotestos- 
terone (Vrij Universiteit Hospital Pharmacy, gel preparation) 
was given to one woman for 11 months. Data on serum hor- 
monal levels were available for eight of these 11 patients (Ta- 
ble 1); in all but one patient testosterone treatment was dis- 
continued 6 weeks before surgery. Serum testosterone levels 
normalized in these women. 
Cryostat sections, 5-p thick, air dried, and subsequently 
fixed in 4% buffered formalin for 10 minutes, were dehy- 
drated in chilled methanol and acetone. After washing in 
phosphate-buffered saline (PBS) at PH 7.4, the slides were 
incubated with 5% nonimmune rabbit serum (Dakopatts, 
Glostrup, Denmark) diluted in PBS to block nonspecific anti- 
body binding and immediately incubated overnight with a 
l:lO,OOO dilution of F39.4 ascitic fluid in PBS. To compare 
immunoreactivity of different ovarian samples sections were 
incubated with different titers of F39.4. Titration of the anti- 
body F39.4 was done by l@fold dilutions of the original dilu- 
tion (l:lO,OOO) in PBS. Immunoreactivity was visualized with 
a two-step 
previously. g 
eroxidase antiperoxidase technique as described 
Hydrogen peroxide and diaminobenzidine were 
used as substrates. In negative controls the primary antibody 
was replaced by an irrelevant monoclonal antibody or PBS. 
A semiquantitative estimation of AR positivity was performed 
by scoring the intensity of staining as focally positive (_‘), 
positive (+), or intensely positive (+ +). 
Uterine specimens were available from six female-to-male 
transsexual patients to whom testosterone treatment was ad- 
ministered for a period of 14 to 96 months until surgery. 
Their ages ranged from 22 to 37 years (average, 27 years). 
In addition, uterine specimens were obtained from 10 pre- 
menopausal women 32 to 51 years old and seven postmeno- 
pausal women 56 to 78 years old undergoing hysterectomy 
for nonendocrinological reasons. Specimens were trans- 
ported immediately after surgery to the laboratory. Half of 
each ovary and 0.5-cm” samples of endometrial and myome- 
trial tissue were snap-frozen in liquid nitrogen. 
Antibody 
The mouse monoclonal antibody F39.4 (Sanbio, Uden, 
the Netherlands) specific for human AR was raised against 
an oligopeptide corresponding to amino acids 301 to 320 in 
the N-terminal domain of human AR.‘*,” This antibody is 
able to detect the presence of ARS by a simple immunohisto- 
chemical method. Previously we showed that the immunore- 
Paraffin sections, 5-p thick, were cut and mounted on 3 
aminopropyltriethoxysilane-coated slides (Sigma, St Louis, 
MO) to prevent detachment resulting from the high tempera- 
ture present during antigen retrieval treatment. The sections 
were placed in a 60°C oven for overnight drying. After depara- 
ffinization and rehydration endogenous peroxidase activity 
was blocked with 3% H200 in methanol. Sections then were 
placed in a plastic box containing 200 mL of 0.01 mol/L citric 
acid monohydrate (Merck, Darmstadt, Germany) adjusted to 
pH 6.0 with NaOH and heated in a microwave oven (Miele 
M696, Vianen, the Netherlands) for 3 X 5 minutes at 700 W, 
during which time the fluid level was checked every 5 minutes 
and filled when necessary. The sections were allowed to cool 
to room temperature and were rinsed with PBS. Then they 
were preincubated for 15 minutes at room temperature with 
nonimmune goat serum (Dakopatts, Glostrup, Denmark) di- 
luted in PBS (1: 10). Next the primary antibody F39.4, diluted 
1:5000 in PBS, was applied for overnight incubation at 4°C. 
After rinsing in PBS the sections were subsequently incubated 
with biotinylated goat antimouse antibody (Dakopatts) di- 
luted in PBS (1:400) for 30 minutes in streptavidin-biotin- 
peroxidase complex (Strept-ABC; Dakopatts) for 30 minutes, 
TABLE 1. Pretreatment and Post-treatment Serum Hormonal Levels From Eight Female Transsexual Patients 
Patient 
No. 
Date of 
Birth 
Start of 
Androgen 
Treatment/ 
Date of 
Surgery 
Androgen 
Treatment 
1.H (&I.) 
Pret Post$ 
FSH (p/L) 
Pre Post 
E2 (pmol/ 
L) 
Pre Post 
TE (nmol/ 
L) ~- 
Pre Post PR (/l/I.) 
1* 08-0.3-63 0%88/ 12-89 Andriol 7.7 0.1 5.5 2.5 - 181 - 2.7 0.27 
2* 05-l 1-63 08-85/07-90 Andriol 3.5 - 2.5 - 640 - I.8 3.6 0.32 
3 09-14-63 12-88/05-90 Andriol 3.3 10.5 11.9 3.8 - 2.7 1.7 0.26 
4 06-28-67 08-88/02-90 Andriol - 9.6 9.4 - 159 - 1 .F) 
5 0610-55 0676/05-90 Testoviron - - - - - - - - - 
6 12-18-86 01-89/12-89 Andriol 4.5 9.3 13.7 8.9 - 618 t1 1.2 0.52 
7 03-22-55 05-84/05-90 Sustanon 4.7 1.6 5.4 6.6 - 344 - 30.1 0.14 
8 03-29-68 08-89/O&90 DHT 8.7 0.4 3.0 1.2 231 56 2.2 0.8 0.31 
Ahbreviations: LH. luteinizing hormone; FSH, follicle stimulating hormone; E2, estradiol; TE, testosterone; PR, progesterone. 
* Pretreatment cycle irregular. Androgen treatment: Andriol 40 mg two tablets twice daily; Sustanon 250 mg/IM/2 wk. 
t Pretreatment level. 
: Posttreatment level. 
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and in 3,3’diaminobenzidine tetrahydrochloride (Fluka, Ba- 
sel, Switzerland) for 7 minutes. Between each incubation step 
the sections were rinsed three times in PBS. Negative controls 
were included, replacing F39.4 antibody with PBS for all the 
tissues investigated. Mayer’s hematoxylin was used for nuclear 
counterstaining. 
Western Blot Analysis 
Western blot analysis was performed on ovarian and uter- 
ine tissues of androgen-treated female transsexual patients 
confirming the presence of human ARs. Frozen tissue speci- 
mens were pulverized under liquid nitrogen. One hundred 
milligrams of the resulting powder was suspended in 200 ~1, 
of buffer (40 mmol/L of Tris, 1 mmol/L of ethylenediamine- 
tetraacetic acid, 10% [v/v] glycerol, 0.08% [w/v] sodium do- 
cecylsulfate [SDS], 10 mmol/L of dithiothreitol [DHT], 0.5% 
[w/v] deoxycholate, and 1% [v/v] Triton X100) in the pres- 
ence of inhibitors of proteolytic breakdown [0.6 mmol/L phe- 
nyl-methyl-sulfonyl fluoride], 0.5 mmol/L Bacitracin, and 
0.25 mmol/L of leupeptine). After lysis for 20 minutes on ice 
the suspension was centrifuged for 10 minutes at 1,700 g. The 
supernatant was stored at -80°C until use. From 200 & of 
tissue lysate and 50 PL of LNCaP cytosol ARs were immuno- 
precipitated with AR-specific monoclonal antibody F39.4 com- 
plexed to goat-antimouse immunoglobulin Gagarose, fol- 
lowed by SDSpolyacrylamide gel electrophoresis, as described 
previously.” Western blotting was performed with mono- 
clonal antibody F39.4. The procedure for protein detection 
was described in detail previously.“,‘s 
RESULTS 
Histomorphological Features of Ovaries and 
Uterine Tissue From Female Transsexual 
Patients 
Transsexual ovaries from female transsexual pa- 
tients were grossly enlarged and displayed an increased 
number of cystic follicles and atretic follicles (Fig 1); 
ovarian cortices were collagenized and thicker (Fig 2). 
Theta interna hyperplasia and luteinization were uni- 
formly observed in cystic follicles. Stromal hyperplasia 
accompanied frequently by clusters of luteinized cells 
was a constant finding. 
Histological examination of the uteri of female 
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transsexual patients showed inactive endometria. The 
glands were small and tubular, mostly lined by a single 
layer of cuboidal or low columnar epithelium, and a 
few glands displayed slight stratification. No mitoses 
were seen. In two cases endometria showed atrophy 
with small, tubular, rather sparse glands. Endometrial 
stroma showed no significant changes. In one of these 
cases tubal metaplasia was present. No endometrial 
samples showed any evidence of secretory activity. The 
myometria in the uteri of female transsexual patients 
were histologically unremarkable. 
Androgen Receptor Expression in Normal 
Ovarian Tissue 
In the seven ovaries from postmenopausal women 
the germinal (coelomic) epithelia and the epithelial 
lining of inclusion cysts showed strong nuclear reactivity 
for ARs. The underlying stroma exhibited a patchy 
staining reaction for ARs (Fig 3). Cryostat sections of 
the ovarian tissue obtained at autopsy as well as the four 
normal paraffin-embedded ovaries from premeno- 
pausal women showed positive nuclear staining of gran- 
ulosa cells and a small proportion (10%) of stromal 
cells (Fig 4). The corpus lutea demonstrated positive 
nuclear staining for ARs, but some selective cytoplasmic 
staining also was observed. The same cytoplasmic stain- 
ing was found in control sections using a nonspecific 
antibody indicating that the cytoplasmic staining of lu- 
tein cells was nonspecific. Germinal epithelia and 
stroma always were negative in the control sections. 
Androgen Receptor Expression in Ovarian 
Tissue of Female Transsexual Patients and 
Patients With PCOD 
In 13 ovaries obtained from 11 female transsexual 
patients ovarian stroma showed a diffuse and intense 
nuclear AR expression. Granulosa and thecal cells of 
the follicle cysts present in 11 ovarian samples exhibited 
strong nucIear reactivity as well (Fig 5). Ovarian tissue 
from one frozen ovary and nine paraffin-embedded ova- 
ries from patients with PCOD showed similar findings 
with intense nuclear staining of granulosa and thecal 
cells and diffuse, intense staining of ovarian stroma (Fig 
6). Data on AR expression in ovaries of normal controls 
and patients with PCOD are listed in Table 2. 
FIGURE 1. Section of ovary of female transsexual patient 
showing multiple cystic atretic follicles. (Hematoxylin-eosin (HE) 
stain; original magnification x4.) 
To substantiate our impression (judging from the 
intensity of immunohistochemical staining) that ovaries 
from female transsexual patients had higher levels of 
ARs than did ovaries from normal postmenopausal 
women, titration was performed with F39.4 in three 
ovaries from normal controls and three ovaries from 
female transsexual patients. In contrast to the ovaries 
from normal postmenopausal women in which the 
staining was heterogeneic (with variation in intensity 
and a lower percentage of positive cells), virtually all 
ovarial stromal cells from female transsexual patients 
remained positive even at the greatest dilution of 
1:32,000 (Table 2). The intensity of staining of stromal 
cells from female transsexual patients diminished with 
higher dilutions showing a dilution response and prov- 
ing that the staining of stromal cells was not an artifact. 
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FIGURE 2. Thickened collagenized tunica albuginea in ovary 
of female transsexual patient. (HE stain; original magnification 
x380.1 
Androgen Receptor Expression in Uterine 
Tissue of Female Transsexual Patients and 
Normal Women 
Myometrial and endometrial stromal cells from all 
six uteri of female transsexual patients displayed an 
intense nuclear reaction for ARs. In contrast, endome- 
trial glandular epithelia remained completely negative 
(Figs 7 and 8). Uteri of premenopausal women tested 
generally were negative for AR in myometrium and en- 
dometrium, except in two cases in which a focal and 
faint staining of endometrial stromal cells and of 
smooth muscle cells of myometrium was seen. 
Three uteri of postmenopausal women exhibited 
a moderately intense AR expression in myometrium, 
and in one of these endometrial stroma also contained 
focal areas with a faint nuclear reactivity for F39.4 (Ta- 
ble 3). None of the uterine tissues studied displayed 
staining of blood vessel walls. 
Western Blot Analysis 
With F39.4 a 1 lO-kd doublet was observed in uter- 
ine tissues of female transsexual patients corresponding 
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FIGURE 4. Normal ovary. Granulosa cells of antral follicle ex- 
hibit strong positivity for AR. (No nuclear counterstain; original 
magnification x380.) 
to the well established molecular weight of the phos- 
phorylated and nonphosphorylated variants of AR (Fig 
9).‘” In the uterine tissue of a nontreated premeno- 
pausal woman this 110 kd doublet also was detectable. 
The large low molecular weight band in the Western 
blot of the uteri of androgen-treated female transsexual 
patient represents degradation products. The strong 
variation in degradation of the llO-kd AR molecule 
precludes a reliable quantitation of AR on the basis of 
Western blot analysis. 
DISCUSSION 
To date a limited number of studies have described 
the presence of ARs in human endometrium.57 In our 
study we detected the presence of ARs in human endo- 
metrium and myometrium and compared the localiza- 
tion of AR in normal human ovary with that in the 
ovaries of female transsexual patients receiving large 
doses of androgen. 
Cytosolic detection of ARs in nuclear fractions of 
FIGURE 3. Normal ovary. Epithelial lining of inclusion cyst 
shows strong nuclear reactivity for AR; stroma shows patchy 
staining reaction. (No nuclear counterstain; original magnifi- 
cation x380.) 
FIGURE 5. Ovary from female transsexual patient. Granulosa 
cells (short arrow), thecal cells (long arrow), and stroma show 
intense nuclear AR expression. (No nuclear counterstain: origi- 
nal magnification x380.) 
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FIGURE 6. Ovary from patient with PCOD showing intense FIGURE 7. Uterine tissue from female transsexual patient. 
nuclear staining of granulosa cells and stroma. (No nuclear Myometrium displays an intense nuclear reaction for AR (HE 
counterstain; original magnification x380.) counterstain; original magnification x380.) 
rat ovaries by classical binding methods was reported 
by Schreiber et al” and Schreiber and Ross.” Our re- 
sults on human ovarian tissue showing the presence of 
ARs in granulosa-thecal cells, stroma, and corpus lu- 
teum confirm those of Horie et al!’ in human ovary. In 
the ovaries of rhesus monkeys ARs were observed in 
germinal epithelium, stromal fibroblasts, granulosa 
cells, and corpus luteurn.’ The results of these studies 
are consistent with the concept that androgens inter- 
acting with ARs play an essential role in follicular 
growth and maturation, atresia, and luteinization in an 
either autocrine or paracrine manner. They are thus 
consistent with the hypothesis that androgens could 
play a direct role in ovarian function regulation via a 
receptor-mediated mechanism.“~‘” 
Distinct from ARs, estrogen receptors are selec- 
tively localized in germinal epithelium and not in antral 
follicle, corpus luteum, or stromal cells of normal ovary. 
Progesterone receptors have been detected in stromal 
and thecal cells and not in granulosa cells.” Ovaries of 
the female transsexual patients exhibited an intense AR 
expression by the granulosa-thecal cells of the follicles 
as well as by stroma. The presence of AR molecules 
in the ovaries and uterine tissues of androgen-treated 
female transsexual patients was further substantiated by 
Western blot analysis showing the characteristic llO- 
kd doublet in tissue homogenates. Our titration study 
TABLE 2. Androgen Receptor lmmunohistochemical 
Expression in Ovaries of Normal Controls and Female 
Transsexual Patients 
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demonstrated that AR expression by ovarian stromal 
cells in the ovaries of androgen-treated female transsex- 
ual patients is more uniform and more intense than it 
is in the ovaries of nontranssexual (premenopausal and 
postmenopausal) women. We also demonstrated in 10 
ovaries from women with PCOD that the stromal cells 
exhibited a similar diffuse and intense AR staining as 
is the case in the ovaries of androgen-treated female 
transsexual patients. The hyperplasia of stromal cells 
in the ovaries of androgen-treated female transsexual 
patients and the ovaries of patients with PCOD provides 
an additional argument for androgen-mediated func- 
tional effects in human ovary. In PCOD stromal hyper- 
plasia may be a consequence of either prolonged expo- 
sure to elevated androgens or of hypersensitivity of the 
stromal cells to androgens. The increased presence of 
AILS in the hyperplastic stroma of ovaries of patients 
with PCOD and in ovaries of androgen-exposed female 
transsexual patients implies a functional role of AR in 
this morphological change. 
It should be noted that in most of these female 
transsexual patients androgen therapy was discon- 
Ovarian Stroma Granulosa Cells 
Normal ovary %* (5/12)t; + (7/12) + (12/12) 
Ovary from female 
transsexual 
patient ++ (13/13) + (3/l@; ++ (7/10) 
Ovary from 
patient with 
PCOD + (l/10); ++ (9/1(J) + (l/10); ++ (9/10) 
* 2, +, ++, intensity of staining. 
t Fraction of examined cases. 
FIGURE 8. Uterine tissue from female transsexual patient. En- 
dometrial stroma cells stain strongly positive for AR. Note the 
negative glandular epithelium and lymph follicle (arrow). (No 
nuclear counterstain: original magnification x380.) 
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tinued 6 weeks before surgery, resulting in low testoster- 
one levels (Table 1). Apparently the androgen-induced 
upregulation of ARs in ovarian stroma is quite stable 
and persists for a considerable time after removal of 
the inducing agent. 
Ruizeveld et al’ studied AR expression immunohis- 
tochemically in several human tissues and showed AR 
localization in male sex organs, vagina, and cervix, al- 
though in a small series of uterine tissues no immunore- 
activity for ARs was detectable. In this larger series of 
uteri of premenopausal and postmenopausal women 
focal AR expression occasionally was detected with im- 
munohistochemistry in human endometrial stroma and 
myometrium. Western blot analysis of untreated uterine 
tissue confirmed the presence of a 1 lo-kD AR molecule 
but did not allow quantitation. The observed increase 
in AR expression in the ovaries, and particularly in the 
endometria and myometria of female transsexual pa- 
tients receiving long-term androgen therapy, may be 
the result of androgen-mediated up-regulation of AR 
expression. Considering the high turnover of endome- 
trial stromal cells, the possibility of replacement of AR- 
negative stromal cells by AR-positive stromal cells 
should be considered as well. Because the turnover of 
myometrial as well as ovarian stroma is low, the ob- 
served androgen-induced intense positivity with anti-AR 
must be a consequence of androgeninduced AR up- 
regulation within the same cells. 
FIGURE 9. Western blot analysis of lysates of myometrial and 
ovarian tissue of an androgen-treated female transsexual pa- 
tient (lanes 1 and 2) and of myometrial tissue of a nontreated 
premenopausal woman (lane 3). Nuclear fraction of LNCaP 
(lane 4) served as a positive control. The dense low molecular 
weight band in lane 1 represents a 50-kd degradation product 
of AR. TSX, transsexual; prem, premenopausal. 
Autoregulation of AR expression has been de- 
scribed in a few experimental models.‘-5’L’-2” In a human 
prostate carcinoma cell line androgen ablation has 
been shown to down-regulate AR expression.‘” More- 
over, several investigators showed in animal models that 
androgens up-regulate AR expression.“‘,” Autoregula- 
tion of ARs may occur at the transcriptional or posttran- 
scriptional level. Studies performed by Kemppainen e( 
al’” in monkey kidney cells (COS cells) transfected with 
AR gene constructs demonstrated that AR half-life is 
increased in the presence of androgen. This suggests a 
posttranscriptional regulation mechanism. Nonethe- 
less, so far no evidence is available on human AR stabili- 
zation by hormones under physiological conditions. 
Androgen therapy in female transsexual patients 
leads to a striking contrast in its effects on ovarian, 
endometrial, and myometrial tissues. In the ovaries of 
the female transsexual patients the presence of numer- 
ous cystic follicles is associated with hyperplasia of ovar- 
ian stromal and thecal cells. In contrast, the endometria 
of female transsexual patients showed an inactivation 
or even atrophy of the glandular compartment. but 
stromal cells were not significantly affecl.ed. The myo- 
metria of female transsexual patients examined by us 
showed no apparent atrophy or hyperplasia. However, 
functional changes in myometrium may be induced by 
androgens. Thus, Roy et a12’ demonstrated a severalfold 
increase in NAD’-dependent uterine prostaglandin 15- 
hydroxydehydrogenase in androgen-treated female 
transsexual patients. 
The lack of ARs in glandular epithelial cells sug- 
gests that the glandular changes are not a consequence 
of direct interaction of androgen with these epithelial 
cells. It remains to be established whether the androgen 
effect on endometrial glands is mediated by a paracrine 
effect on stromal cells. It is not likely that the inactiva- 
tion of endometrial glands is caused by an altered expo- 
sure to hypophysisderived gonadotropic hormones. 
Previous studie? showed that androgen treatment 
does not substantially alter serum levels of follicle stimu- 
lating hormone or luteinizing hormone. The variety 
in morphological effects of androgens on the female 
genital tract implies that other regulatory proteins also 
determine the outcome of the interaction of androgens 
with ARs in these organs. 
TABLE 3. lmmunohistochemical Analysis of 
Androgen Receptor in Endometria and Myometria of 
Female Transsexual Patients and Premenopausal and 
Postmenopausal Women 
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F.ndometria 
(Stroma) Mynlnetria 
PI-emenopausal WOTIl‘~ll 2* 2t (11 = 7): ” t (n = 7) 
Postmenopausal WOIIICII I -+ (n = 7) 3 + (11 = 7) 
Frmale tt-anssexual patients 6 ++ (11 = 6) 6 ++ (II = 6) 
* Number of caws positive. 
t 2, +. ++, intulsitv of staining. 
: Nurntw ot casts tested 
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